Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000174243 | SCV000225512 | pathogenic | not provided | 2013-02-18 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000672348 | SCV000797446 | likely pathogenic | GM1 gangliosidosis type 2; GM1 gangliosidosis type 3; Mucopolysaccharidosis, MPS-IV-B; Infantile GM1 gangliosidosis | 2018-01-25 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001386115 | SCV001586231 | pathogenic | Mucopolysaccharidosis, MPS-IV-B; GM1 gangliosidosis | 2024-10-22 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu392Valfs*64) in the GLB1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GLB1 are known to be pathogenic (PMID: 18524657). This variant is present in population databases (rs398123348, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with GLB1-related conditions. ClinVar contains an entry for this variant (Variation ID: 92893). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000672348 | SCV005658093 | pathogenic | GM1 gangliosidosis type 2; GM1 gangliosidosis type 3; Mucopolysaccharidosis, MPS-IV-B; Infantile GM1 gangliosidosis | 2024-06-04 | criteria provided, single submitter | clinical testing |